Breast Cancer

, Volume 7, Issue 4, pp 361–369 | Cite as

Optimising treatment of bone metastases by Aredia™ and Zometa™

  • Robert E. Coleman
Luncheon Seminar II


Metastatic bone disease develops as a result of the many interactions between tumour cells and bone cells. This leads to disruption of normal bone metabolism, with the increased osteoclast activity seen in most, if not all, tumor types providing a rational target for treatment. The clinical course of metastatic bone disease in multiple myeloma, breast and prostate cancers is relatively long, with patients experiencing sequential skeletal complications over a period of several years. These include bone pain, fractures, hypercalcaemia, and spinal cord compression, all of which may profoundly impair a patient’s quality of life.

External beam radiotherapy and systemic endocrine and cytotoxic treatments are the mainstay of treatment in advanced cancers. However, it is now clear that the bisphosphonates provide an additional treatment strategy, which reduces both the symptoms and complications of bone involvement. Pamidronate (Aredia™) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases. Current research aims include the evaluation of new potent bisphosphonates such as zoledronic acid (Zometa™). It is hoped that this compound is not only more convenient and easier to administer but also more effective in inhibiting skeletal morbidity. Zometa may also have some direct anticancer activity.

Preclinical studies with Zometa have demonstrated its potential in malignant bone disease. Clinical studies in treatment of hypercalcemia of malignancy have been completed, as have Phase I and II trials in patients with cancer and pre-existing bone metastases. Three randomized, double-blind, controlled Phase III trials are now ongoing to establish the efficacy and safety of Zometa in treatment of bone metastases in patients with osteolytic and osteoblastic lesions. Additionally, new specific molecules such as osteoprotogerin have been developed that are based on our improved understanding of the cellular signalling mechanisms involved in cancer induced bone disease. These potent molecules are now entering clinical trials.

Ongoing research is aimed at trying to define the optimum route, dose, schedule and type of bisphosphonate in metastatic bone disease and their use in the prevention and treatment of osteoporosis in cancer patients. In vitro suggestions of direct anti-cancer activity and some promising clinical data in early breast cancer have resulted in considerable interest in the possible adjuvant use of bisphosphonates to inhibit the development of bone metastases.

Key words

Bone metastases Bisphosphonates Pamidronate Zoledronic acid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Theriault RL, Lipton A, Hortobagyi GN,et al: Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: A randomised, placebo-controlled trial.J Clin Oncol 17:846–854, 1999.PubMedGoogle Scholar
  2. 2).
    Hortobagyi GN, Theriault RL, Porter L,et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases.New Engl J Med 335:1785–1791, 1996.PubMedCrossRefGoogle Scholar
  3. 3).
    Rogers MJ, Watts DJ, Russell RGG: Overview of bisphosphonates.Cancer 80/8 (suppl): 1652–1660, 1997.CrossRefGoogle Scholar
  4. 4).
    Yoneda T, Michigami T, Yi B,et al: Use of bisphos-phonates for the treatment of bone metastasis in experimental animal models.Cancer Treatment Reviews 25:293–299, 1999.PubMedCrossRefGoogle Scholar
  5. 5).
    van der Pluijm G, Lowik C, Papapoulos S: Tumour progression and angiogenesis in bone metastases from breast cancer: new approaches to an old problem.Cancer Treatment Reviews 26:11–27, 2000.CrossRefGoogle Scholar
  6. 6).
    Coleman RE: Pamidronate Disodium in the treatment and management of hypercalcaemia.Reviews in Contemporary Pharmacotherapy 9:147–164, 1998.Google Scholar
  7. 7).
    Body JJ, Bartl R, Burckhardt P, Delmas PD,et al: Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.J Clin Oncol 16:3890–3899, 1998.PubMedGoogle Scholar
  8. 8).
    Body JJ, Lichinitser MR, Diehl IE,et al: Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proceedings ASCO 18:575a, 1999.Google Scholar
  9. 9).
    Berenson JR, Lipton A, Rosen LS,et al: Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), inpatients with osteolytic bone metastases.Blood 88 (Suppl 1): 586a, 1998.Google Scholar
  10. 10).
    Vinholes JJ, Purohit OP, Abbey ME,et al: Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease.Ann Oncol 8:243–1250, 1997.CrossRefGoogle Scholar
  11. 11).
    Coleman RE: Biochemical markers of malignant bone disease. Rubens RD & Mundy GR eds, Martin Dunitz, London, 2000, in press.Google Scholar
  12. 12).
    Body J-J, Coleman RE, Piccart M: Use of bisphosphonates in cancer patients.Cancer Treatment Reviews 22:265–287, 1996.PubMedCrossRefGoogle Scholar
  13. 13).
    Paterson AHG, Powles TJ, Kanis J,et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.J Clin Oncol 11:59–65, 1993PubMedGoogle Scholar
  14. 14).
    Lahtinen R, Laakso M, Palva I,et al: for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma.Lancet 340:1049–1052, 1992.PubMedCrossRefGoogle Scholar
  15. 15).
    McCloskey EV, Maclennan ICM, Drayson M,et al: A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma.Br J Haematology 100:317–325, 1998.CrossRefGoogle Scholar
  16. 16).
    Conte PF, Mauriac L, Calabresi F,et al: Delay in progression of bone metastases treated with intravenous pamidronate: Results from a multicentre randomised controlled trial.J Clin Oncol 14:2552–2559, 1996.PubMedGoogle Scholar
  17. 17).
    Hultborn R, Ryden S, Gunderson S,et al: Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial.Acta Oncologica 35 (suppl5): 73–74, 1996.PubMedCrossRefGoogle Scholar
  18. 18).
    Berenson JR, Lichtenstein A, Porter L,et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.N Engl J Med 334:488–493, 1996.PubMedCrossRefGoogle Scholar
  19. 19).
    Lipton A, Demers L, Curley E,et al: Markers of bone resorption in patients treated with pamidronate.Eur J Cancer 34:2021–2026, 1998.PubMedCrossRefGoogle Scholar
  20. 20).
    Lipton A, Theriault RL, Hortobagyi GN,et al: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term results of two randomised, placebo-controlled trials.Cancer 88:1082–1090, 2000.PubMedCrossRefGoogle Scholar
  21. 21).
    Green JR, MIIller K, Jaeggi KA: Preclinical pharmacology of CGP 42′446, a new potent, heterocyclic bisphosphonate compound.J Bone Miner Res 9:745–751, 1994.PubMedCrossRefGoogle Scholar
  22. 22).
    Bare S, Kimmel D, Binkley N,et al: Zoledronate (CGP-42′446) suppresses turnover without affecting mineralization in cancellous bone of the ovariec-tomized non-human primate.J Bone Miner Res 12 (suppll): S473, 1997Google Scholar
  23. 23).
    Green JR, Hornby SB, Evans GP,et al: Effect of 1-year treatment with zoledronate (CGP 42446) on bone mineral density, bone mechanical properties, and biochemical markers in the ovariectomized rat.J Bone Miner Res Abstract M631, 1996.Google Scholar
  24. 24).
    Binkley N, Kimmel D, Bruner J,et al: Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys.J Bone Miner Res 13:1775–1782, 1998.PubMedCrossRefGoogle Scholar
  25. 25).
    Body JJ, Lortholary A, Romieu G,et al: A dose-finding study of zoledronate in hypercalcaemic cancer patients.J Bone Miner Res 14:1557–1661, 1999.PubMedCrossRefGoogle Scholar
  26. 26).
    Major P, Lortholary A, Hon J,et al: Zoledronic acid is superior to pamidronate in the treatment of tumourinduced hypercalcaemia: A pooled analysis.ASCO Proceedings 19:604a, 2000.Google Scholar
  27. 27).
    Coleman RE, Purohit OP, Black C,et al: Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease.Ann Oncol 10:311–316, 1999.PubMedCrossRefGoogle Scholar
  28. 28).
    Saarto S, Blomqvist C, Valimaki M,et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: A randomised study in premenopausal patients.J Clin Oncol 15:1341–1347, 1997.PubMedGoogle Scholar
  29. 29).
    Powles TJ, Paterson AHG, Nevantaus A,et al: Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer.ASCO Proceedings 17:468a, 1998.Google Scholar
  30. 30).
    Diel I, Solomayer E-F, Costa SJ,et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment.N Engl J Med 339:357–363, 1998.PubMedCrossRefGoogle Scholar
  31. 31).
    Saarto T, Blomqvist C, Virkkunen P,et al: No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients.ASCO Proceedings 18:128a, 1999.Google Scholar
  32. 32).
    Fisher B, Redmond C, Legault-Poisson S,et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positivenode breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the NSABP-16.J Clin Oncol 8:1005–1018, 1990PubMedGoogle Scholar
  33. 33).
    Fisher B, Brown A, Dimitrov N,et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: Results from NSABP B-15.J Clin Oncol 8:1483–1496, 1990PubMedGoogle Scholar
  34. 34).
    Buzzoni R, Bonadonna G, Valagussa P,et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.J Clin Oncol 9:2134–2140, 1991PubMedGoogle Scholar
  35. 35).
    Rubens R, Coleman R: Bone metastases. In: Abeloff et al eds, Clinical Oncology, Churchill Livingston, Inc., New York, pp643–665, 1995.Google Scholar
  36. 36).
    Paterson AHG: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.Cancer 88:3038–3946, 2000.PubMedCrossRefGoogle Scholar
  37. 37).
    Percival RC, Urwin GH, Watson ME: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.Eur J Surg Oncol 113:41–49, 1987.Google Scholar
  38. 38).
    Clarke NW, McClure J, George NJR: Morphometric evidence for bone resorption and replacement in prostate cancer.Br J Urol 68:74–80, 1991.PubMedCrossRefGoogle Scholar
  39. 39).
    Honore P, Luger NM, Sabino AC,et al: Osteoprotogerin blocks bone cancer-induced skeletal destruction. Skeletal pain and pain-related neurochemical re-organisation of the spinal cord.Nature medicine 6:521–528, 2000.PubMedCrossRefGoogle Scholar
  40. 40).
    Kong Y-Y, Yoshida H, Sarosi O,et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.Nature 397:315–323, 1999.PubMedCrossRefGoogle Scholar
  41. 41).
    van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ,et al: Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment.Lancet ii:983–985, 1987.CrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2000

Authors and Affiliations

  • Robert E. Coleman
    • 1
  1. 1.Yorkshire Cancer Research Department of Clinical Oncology, Cancer Research CentreWeston Park HospitalUK

Personalised recommendations